Screening Campaigns for Tuberculosis

1 Mar 2010
by Working Group


Drug discovery teams around the world have been actively selecting targets that are likely to be important in killing dormant or very slowly replicating tuberculosis in an effort to shorten the time to cure; for drug sensitive TB, six to nine months treatment time and drug resistant TB, up to two years treatment time. Some of these targets have been processed through high throughput screening (HTS) campaigns comprising millions of compounds but little to no follow up on the hits from these screening campaigns has been reported. Often when a person discusses these targets with the scientists that performed the HTS, the standard response is that these targets are “non-druggable”.

Whether it’s a lousy target, the compound collection screened was or was not the best fit or there was limited bacterial potency in the follow-up bacterial cell assays remains unclear. In an effort to determine what targets have or have not been processed and why, The Stop TB Working Group for New Drugs Biology/Targets Sub-group is seeking to triage the best drug targets. First, we are attempting to understand what has been done to date by different groups through surveys and direct communication.

Out of frustration or a lack of productive results, many scientists are abandoning target based screens in lead optimization efforts in favor of phenotypic screens using whole cell bacteria. However, this approach leaves medicinal chemists working blind with respect to new directions in lead optimization efforts to drive compound potency, and for M. tuberculosis, the question of cell culture media and carbon sources can derail a drug discovery effort due to altered bacterial physiology. Drug screening campaigns that integrate both physiologically-relevant phenotypic screens and target-based efforts may be the middle path and a faster way to generating new drug leads for tuberculosis.

Would you like to get involved? What targets are you working on? What targets have you worked on? What challenges or hurdles did you come across? Please contact the WGND Biology/Targets subgroup with any information that you believe will aid and speed TB drug discovery.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...